| Title |
Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
|
|---|---|
| Published in |
EJNMMI Research, August 2014
|
| DOI | 10.1186/s13550-014-0035-5 |
| Pubmed ID | |
| Authors |
Idris Bahce, Marc C Huisman, Eline E Verwer, Rogier Ooijevaar, Firdaouss Boutkourt, Danielle J Vugts, Guus AMS van Dongen, Ronald Boellaard, Egbert F Smit |
| Abstract |
The aim of this pilot study was to evaluate whether the uptake of (89)Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor (89)Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) (89)Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. This pilot study shows that (89)Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 5% |
| Netherlands | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 39 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 30% |
| Student > Ph. D. Student | 8 | 19% |
| Student > Bachelor | 3 | 7% |
| Other | 3 | 7% |
| Professor | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 9 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 44% |
| Chemistry | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 10 | 23% |